AstraZeneca Another Executive Departs, Previously Went Viral for "Soul-Crushing" Medical Insurance Negotiation Price Cuts

Does AI · Huang Bin’s departure reflect a strategic shift for multinational pharmaceutical companies in China?

Jiemian News Reporter | Chen Yang

Jiemian News Editor | Xie Xin

According to a report by Yicai Finance on the evening of March 18, Huang Bin, Vice President of AstraZeneca China and Head of Market Access, will be leaving his position. There are also reports that his term will end on March 20. That evening, Jiemian News contacted AstraZeneca China for confirmation and inquired about who will be responsible for market access work moving forward. As of press time, no response has been received. Currently, information about Huang Bin still appears on AstraZeneca China’s official website.

Jiemian News screenshot from AstraZeneca China’s official website

Huang Bin is a veteran who has worked at AstraZeneca China for over twenty years, with extensive experience in market access.

Public information shows that he earned a Bachelor’s degree in Chemistry and a Master’s degree in Organic Chemistry from Beijing Normal University. He previously worked at Eli Lilly for nine years, serving as a Regulatory Affairs Specialist, Senior Specialist, and Manager. In 2004, Huang Bin joined AstraZeneca China, where he served as Director and Executive Director of Regulatory Affairs.

In 2013, Huang Bin was promoted to Vice President of Government Affairs and Market Access, overseeing AstraZeneca China’s government and non-governmental organization affairs, public relations and corporate communications, nationwide distributor operations, and the development of AstraZeneca China’s emerging markets and community business; he also led AstraZeneca China’s work in healthcare insurance, bidding, and hospital access.

Huang Bin became well known in the industry during the 2019 national healthcare negotiations, especially for the famous scene involving a “soulful price cut” of 4 cents.

That year, the negotiation drug was AstraZeneca’s blockbuster Type 2 diabetes medication Dapagliflozin (brand name: Forxiga). After multiple price offers and two rounds of leaving the table for approval, Huang Bin offered a price of 4.44 yuan per tablet on behalf of AstraZeneca. The negotiation experts from the healthcare insurance side responded, “4 is too high; Chinese people find it hard to accept, so lower it by 4 cents.” Ultimately, Dapagliflozin was successfully included in the national medical insurance catalog at a price of 4.36 yuan per tablet, a reduction of over 70%, setting a global lowest price.

Huang Bin at the healthcare insurance negotiation scene. Screenshot from CCTV News

Since then, Huang Bin has led multiple national negotiations. In 2020, when asked by the media whether the negotiations went smoothly, Huang Bin’s reply, “Just look at my expression,” became widely discussed again.

However, with the normalization of industry policies such as healthcare cost control and volume-based procurement, as well as the continuous improvement of domestic pharmaceutical R&D capabilities, the era of multinational pharmaceutical companies “making easy money” in China is gone. Companies are now focusing on core therapeutic areas, innovation R&D, and operational efficiency.

Against this background, coupled with the emergence of the case of AstraZeneca China’s former President Wang Lei in 2024, AstraZeneca China has undergone multiple organizational adjustments and leadership changes over the past one or two years. Many of these involve veteran employees who have worked at AstraZeneca China for many years, including Huang Bin, leaving the company.

For example, in September 2025, former AstraZeneca China Vice President and Head of Medical Affairs Yang Haiying, as well as former Vice President and Head of Human Resources Liao Peishan, left their positions. In April of the same year, Liu Qian, former General Manager of AstraZeneca China’s Respiratory and Gastrointestinal Business Unit, also left and subsequently joined Astellas as the General Manager of Astellas China.

In addition, over the past six months, AstraZeneca China has implemented several structural changes, including establishing a dedicated Medical Affairs team within therapeutic areas, to support business development; creating a new Early Pipeline Department to focus on clinical trials from Phase 3 to 18 months before market launch; and establishing a Full Product Channel Business Unit to integrate previously scattered retail, county, and other business lines.

During this period, the government affairs and market access department previously led by Huang Bin has been further subdivided into Corporate Affairs and Market Access departments. Huang Bin has been appointed head of the Market Access Department, overseeing market access work, which may indicate a reduction in his scope of authority.

On the other hand, with ongoing optimization of national healthcare policies encouraging innovation, the first edition of the Commercial Insurance Innovative Drug List was implemented in December 2025 to facilitate coverage of high-value innovative drugs; early 2026 will see the implementation of a reference drug pre-communication approach to improve the efficiency and scientific basis of drug inclusion in medical insurance through pre-communication. These developments are likely to increase demand for talent in drug access.

Currently, Huang Bin’s future plans remain unknown.

In terms of performance, AstraZeneca’s revenue for 2025 is projected at $58.739 billion, an 8% increase year-over-year. Revenue in China is expected to reach $6.654 billion, up 4%, accounting for approximately 11%.